Oncology Institute (DFPH) Liabilities and Shareholders Equity (2019 - 2026)

Oncology Institute (DFPH) has 8 years of Liabilities and Shareholders Equity data on file, last reported at $168.2 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 2.58% year-over-year to $168.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $656.3 million (down 5.64% YoY) and the FY2025 annual result came in at $164.7 million, down 4.67% from the prior year.
• Liabilities and Shareholders Equity rose to $168.2 million in Q1 2026, from $164.7 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $283.8 million in Q3 2022 to a low of $159.8 million in Q2 2025.
• A 5-year average of $199.4 million and a median of $189.7 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity advanced 28.62% — and 2023, when it slipped 23.06%.
• Tracing DFPH's Liabilities and Shareholders Equity over 5 years: stood at $261.7 million in 2022, then declined by 20.04% to $209.2 million in 2023, then slipped by 17.46% to $172.7 million in 2024, then retreated by 4.67% to $164.7 million in 2025, then increased by 2.17% to $168.2 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $168.2 million (Q1 2026), $164.7 million (Q4 2025), and $163.6 million (Q3 2025), per Business Quant data.